Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
A 35-year-old man with painful and difficult urination underwent 18 F-FDG and Al 18 F-Thretide PET/CT scans after a pelvic MRI suggested a prostate mass. The 18 F-FDG and Al 18 F-Thretide PET/CT scans revealed a prostate mass accompanied by an intravenous tumor thrombus. Both the prostate mass and the intravenous tumor thrombus demonstrated increased FDG uptake. Intense PSMA activity was observed in both lesions, with the intravenous tumor thrombus showing considerably higher PSMA activity compared with its FDG uptake. Histologic analysis of the biopsy confirmed the diagnosis of prostatic synovial sarcoma. PSMA immunohistochemistry showed high PSMA expression in the vascular endothelial cells within the tumor.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/RLU.0000000000005886 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The treatment of intravascular leiomyomatosis with different clinical manifestations: Two case reports.
Medicine (Baltimore)
September 2025
Department of Gynecology and Obstetrics, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
Rationale: Intravascular/intravenous leiomyomatosis (IVL) is a rare benign smooth muscle cell tumor with malignant biological behavior. The early diagnosis of IVL is challenging, and the range of treatment options is extensive.
Patient Concerns: Herein, we present 2 cases of IVL that present markedly different clinical presentations.
Cytoreductive Surgery with Radical Pleurectomy/Decortication and Intraoperative photodynamic therapy as a treatment for Stage IVa and pleural recurrence thymic tumors.
Photodiagnosis Photodyn Ther
September 2025
China Medical University, Hsin-Chu Hospital. Electronic address:
Background: Managing stage IV thymoma with pleural spread or recurrence remains a complex clinical challenge. While complete resection is considered essential for achieving long-term survival, its feasibility and outcomes vary. Inspired by surgical strategies used in malignant pleural mesothelioma, we applied a multimodal approach combining extensive thymectomy, cytoreductive lung-preserving pleurectomy/decortication, and intraoperative photodynamic therapy (PDT) to enhance local control and survival outcomes.
View Article and Find Full Text PDFAdjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): 10-year clinical outcomes and post-hoc analysis by molecular classification from a randomised phase 3 trial.
Lancet Oncol
September 2025
Department of Radiation Oncology, Leiden University Medical Centre, Leiden, Netherlands.
Background: The PORTEC-3 trial investigated the benefit of chemoradiotherapy versus pelvic radiotherapy alone for women with high-risk endometrial cancer. We present the preplanned long-term analysis of the randomised PORTEC-3 trial with a post-hoc analysis including molecular classification of the tumours.
Methods: PORTEC-3 was an open-label, multicentre, randomised, international phase 3 trial.
Safety and Efficacy Assessment of Trastuzumab Emtansine in Indian Patients With Human Epidermal Growth Factor Receptor 2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer Previously Treated With Trastuzumab and a Taxane: An Open-Label, Single-Arm, Phase IV Study.
Asia Pac J Clin Oncol
September 2025
Roche Products India Pvt. Ltd, Mumbai, India.
Introduction: Trastuzumab emtansine (T-DM1), an antibody-drug conjugate, targets tumor cells overexpressing human epidermal growth factor receptor 2 (HER2). This single-arm, phase IV study assessed the safety and efficacy of T-DM1 in Indian patients with HER2-positive, locally advanced, or metastatic breast cancer previously treated with trastuzumab and a taxane.
Methods: Patients received T-DM1 (3.
Blockade of metastasis by targeting circulating tumor cells with platelet encapsuled oncolytic adenovirus.
Biomaterials
September 2025
Institute of Breast Health Medicine, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University and Collaborative Innovation Center, Chengdu, Sichuan, 610041, PR China. Electronic address:
Host immune elimination largely limits the application of oncolytic viruses in clinics. Here, we rationally design a bioactive platelet-based oncolytic adenovirus delivery system. Upon loading adenoviruses, platelets are transformed to a pro-endocytosis status, which facilitates their internalization by circulating tumor cells (CTCs).
View Article and Find Full Text PDF